Sweden opens inquiry into suspect flu vaccine

Aug 18, 2010

Sweden's Medical Products Agency opened an inquiry Wednesday into vaccinations for swine flu made by British pharmaceutical company GlaxoSmithKline, suspected of provoking narcolepsy.

"The MPA has received six reports from health care professionals regarding as suspected adverse drug reaction following Pandemrix ," it said in a statement.

"The agency will, in consultation with external experts, assess the possible relationship between the vaccination and the reported reactions."

The reports concern children aged between 12-16 years who developed symptoms compatible with narcolepsy, a chronic sleeping disorder, that occurred one to two months after vaccination against the H1N1 pandemic.

The Medical Products Agency said it was in contact with European Union member states for information on any similar reports in other countries.

Finland is also looking into the possible link between narcolepsy and the vaccination, in particular Pandemrix, following an increase in the sleeping disorder among children this spring, the Finish news agency STT said.

The preliminary results from the investigation are expected by the end of this year.

In the European Union around 30 million people were vaccinated using Pandemrix. Sweden bought 18 million doses, which was enough to provide two injections for each person in its 9.3 million population.

According to Finland's National Health Institute, 2.5 million Finns were vaccinated against swine flu. Some 750 showed side effects, namely fevers, headaches and coughing, and one case was linked to narcolepsy.

Explore further: Added benefit of vedolizumab is not proven

add to favorites email to friend print save as pdf

Related Stories

EU drug agency: License 2 swine flu vaccines

Sep 25, 2009

(AP) -- The European Union's drug regulator recommended Friday that two swine flu vaccines be licensed in the 27-nation bloc to ensure their availability before the start of the normal flu season.

Recommended for you

Added benefit of vedolizumab is not proven

7 hours ago

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Caliban
not rated yet Aug 19, 2010
It would be interesting, indeed, to see the overall numbers for adverse effects resulting from the various H1N1 vaccines, broken down according to country, age, sex, symptom(s), formulation, and manufacturer.